Articles: function.
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: assessing the function of the right side of the heart .along with diagnosing of pulmonary hypertension and studying the hemodynamic abnormalities, thus Studying functional limitations of pulmonary hypertension on COPD patients. ⋯ The following authors have nothing to disclose: Medhat Soliman, Youssef Ameen, Usama AboelhassanNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Diffuse Lung Disease Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Diffuse alveolar hemorrhage (DAH) is a life threatening condition; it has been associated with many etiologies, including exogenous agents or drugs. Irrespective of its causes, the clinical, radiographic, and histopathological features of DAH may be similar. Hyaluronic acid (HA) injectable gels have been available for the general market since 2003 as cosmetic dermal fillers and skin booster. It is general belief that HA is a safe product. We describe a rare case of DAH caused by the use of hyaluronic acid gels. ⋯ The following authors have nothing to disclose: Jose Basora, Ricardo Fernandez, Modesto GonzalezNo Product/Research Disclosure Information.
-
Tuberculosis Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Endobronchial tuberculosis (EBTB) is defined as tuberculosis infection of tracheobronchial tree with microbial and histopathological evidence. It is present in 10-40% of patients with active pulmonary tuberculosis, and it is often misdiagnosed as bronchial asthma or lung cancer. We report a patient with endobronchial tuberculosis with a metastasis-like lesion of thoracic vertebra (T11). ⋯ The following authors have nothing to disclose: Chhar Bun PaulNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: We report a patient in whom pleuroperitoneal communication was diagnosed following the initiation of peritoneal dialysis (PD), in whom the PD could be continued after thoracoscopic partial resection of the diaphragm. ⋯ The following authors have nothing to disclose: Ryo Takahashi, Yuuichirou TakahashiNo Product/Research Disclosure Information.